The NLRP3 inflammasome is a multi-protein complex in macrophages that promotes release of pro-inflammatory cytokines, leading to inflammatory responses. While it serves an important role in the innate immune system, the dysregulation of this inflammasome is also associated with many adverse health conditions, such as autoimmune disease, diabetes, and other chronic diseases.
"It has been obvious for some time that, when available, drugs that turn off the NLRP3 inflammasome, but not other inflammasomes, will be very useful for treating a variety of inflammatory disorders, from osteoarthritis to Alzheimer's disease and cancer," said Zhenyu Zhong. Zhong is the first author of the recently published Nature paper revealing new mechanics on the NLRP3 inflammasome. The study comes from the work of a UC San Diego-led research team.
"Until now, it was not clearly understood how environmental stress and tissue injury activate the NLRP3 inflammasome and, without such knowledge, it was impossible to rationally design specific inhibitors of the NLRP3 inflammasome," added Zhong.
The team found that the synthesis of mitochondrial DNA is crucial to the NLRP3 inflammasome cellular signaling pathway. In the event of stress-induced stimuli, the NLRP3 protein is activated. It turns out, an enzyme known as cytosine monophosphate kinase 2 (CMPK2) then supplies deoxyribonucleotides for the synthesis of mtDNA. Finally, the association of cytosolic oxidized mtDNA with the NLRP3 inflammasome complex completes its activation, leading to the production of pro-inflammatory cytokine IL-1β by macrophages.
CMPK2 is of particular interest as it belongs to the nucleotide kinase family, some of whose members have already been successfully targeted by the pharmaceutical industry.
"I predict that specific inhibitors of CMPK2 can be easily and rapidly developed," said study senior author Michael Karin. "Once available, such compounds may provide us with new treatments for many diverse untreatable and common illnesses, including osteoarthritis, Alzheimer's disease and lung cancer."